Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31356140

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2019 Oct 10
First author
Rosenberg JE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2019 Oct 10;37(29):2587-2591. doi: 10.1200/JCO.18.02257.
    note
    Source null
    related pmid
    31260641
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Oct;16(10):591. doi: 10.1038/s41571-019-0263-8.
    note
    Source null
    related pmid
    31406342
    relationship
    Comment in
  3. citation
    Cancer Discov. 2019 Oct;9(10):OF1. doi: 10.1158/2159-8290.CD-NB2019-104.
    note
    Source null
    related pmid
    31519705
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2020 Feb 20;38(6):649-651. doi: 10.1200/JCO.19.02393.
    note
    Source null
    related pmid
    31880965
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2020 Feb 20;38(6):651-652. doi: 10.1200/JCO.19.02830.
    note
    Source null
    related pmid
    31880968
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2020 Mar;21(3):e133. doi: 10.1016/S1470-2045(20)30089-9.
    note
    Source null
    related pmid
    32066546
    relationship
    Comment in

Authors and identifiers

  1. name
    Rosenberg JE
    type
    Author
  2. name
    O'Donnell PH
    type
    Author
  3. name
    Balar AV
    type
    Author
  4. name
    McGregor BA
    type
    Author
  5. name
    Heath EI
    type
    Author
  6. name
    Yu EY
    type
    Author
  7. name
    Galsky MD
    type
    Author
  8. name
    Hahn NM
    type
    Author
  9. name
    Gartner EM
    type
    Author
  10. name
    Pinelli JM
    type
    Author
  11. name
    Liang SY
    type
    Author
  12. name
    Melhem-Bertrandt A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Rosenberg JE
    type
    Author
  2. name
    O'Donnell PH
    type
    Author
  3. name
    Balar AV
    type
    Author
  4. name
    McGregor BA
    type
    Author
  5. name
    Heath EI
    type
    Author
  6. name
    Yu EY
    type
    Author
  7. name
    Galsky MD
    type
    Author
  8. name
    Hahn NM
    type
    Author
  9. name
    Gartner EM
    type
    Author
  10. name
    Pinelli JM
    type
    Author
  11. name
    Liang SY
    type
    Author
  12. name
    Melhem-Bertrandt A
    type
    Author
bibliography ids
  1. nci-bib-5b22a56a2a1db629c6333372
book metadata
content sha256
27bb48eff9f40be7275a496d55d3609c7890fab0bb2fbff5ea30d385870c95e5
document type
citation
dois
  1. 10.1200/JCO.19.01140
electronic publication date
display
2019 Jul 29
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31356140
immutable id
pubmed:31356140@27bb48eff9f40be7275a496d55d3609c7890fab0bb2fbff5ea30d385870c95e5
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
29
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2592-2600
volume
37
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2019 Oct 10;37(29):2587-2591. doi: 10.1200/JCO.18.02257.
    note
    Source null
    related pmid
    31260641
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Oct;16(10):591. doi: 10.1038/s41571-019-0263-8.
    note
    Source null
    related pmid
    31406342
    relationship
    Comment in
  3. citation
    Cancer Discov. 2019 Oct;9(10):OF1. doi: 10.1158/2159-8290.CD-NB2019-104.
    note
    Source null
    related pmid
    31519705
    relationship
    Comment in
  4. citation
    J Clin Oncol. 2020 Feb 20;38(6):649-651. doi: 10.1200/JCO.19.02393.
    note
    Source null
    related pmid
    31880965
    relationship
    Comment in
  5. citation
    J Clin Oncol. 2020 Feb 20;38(6):651-652. doi: 10.1200/JCO.19.02830.
    note
    Source null
    related pmid
    31880968
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2020 Mar;21(3):e133. doi: 10.1016/S1470-2045(20)30089-9.
    note
    Source null
    related pmid
    32066546
    relationship
    Comment in
outcomes validated
false
pmid
31356140
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
3287613fb51108d7ce67be79563bd492ec065ef8c6dd6840e06cb7a0858152f0
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2019 Oct 10
precision
day
year
2019
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31356140/
title
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

Preserved source evidence · Not medical advice